Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2020-03-12 Annual Report
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
ANNUAL REPORT
Annual Report FY 2019
2020-03-12 English
results of the Annual General Meeting of shareholders of the Company, held today, Wednesday, January 29, 2020
AGM Information Classification · 98% confidence The document is explicitly titled "Form 6-K" and is a "Report of Foreign Private Issuer" filed with the SEC for the month of January 2020. The content announces the results of the Annual General Meeting (AGM) of shareholders, detailing the approved proposals, which include the re-appointment of auditors and the re-election/election of directors and the CEO. Since the document reports the *results* of the AGM, it aligns best with the AGM Information category (AGM-R), which covers presentations and materials shared during the AGM. Although it is filed on a Form 6-K, the substance is the AGM outcome.
2020-01-29 English
results of the Annual General Meeting of shareholders of the Company, held today, Wednesday, January 29, 2020
Report Publication Announcement Classification · 98% confidence The document is very short (1879 characters) and explicitly states, "Attached hereto is a report on *f6k012920_xtlbiopharmaEDGAR2_Bannerless_isa.pdf*". This structure—a brief announcement referencing an attached or linked primary document—fits the definition of a Report Publication Announcement (RPA) according to Rule 2. The reference to 'EDGAR' and 'U.S. Securities Laws' suggests the attached document is likely a Form 6-K (which is often filed by foreign private issuers and relates to material events), but since this document itself is only announcing the publication of that report, the classification must be RPA.
2020-01-29 English
REPORT OF FOREIGN PRIVATE ISSUER
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It announces the results of the Annual General Meeting (AGM) held on January 29, 2020, including approvals of re-appointments and elections of directors and appointment of CEO. The content focuses on the AGM resolutions and does not contain detailed financial statements or comprehensive reports. The document length is 4028 characters, which is relatively short and primarily an announcement of AGM results rather than the full AGM materials or annual report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-01-29 English
Postponement of annual meeting - No legal quorum
AGM Information Classification · 98% confidence The document explicitly states it is an 'Immediate Report of Meeting' and details the 'postponement of meeting' from 29/01/2020 due to 'No legal quorum'. It lists several agenda items, including the discussion of the auditor's report and the re-election of directors, which are typical items for an Annual General Meeting (AGM). Furthermore, the document is a regulatory filing notice to the Israel Securities Authority and the Tel Aviv Stock Exchange regarding a meeting postponement. Since the content is directly related to the scheduling and agenda of a general meeting, the most appropriate classification is AGM-R (AGM Information), as it pertains to the meeting itself, even though it is a postponement notice. It is not a DEF 14A (Remuneration) or a DVA (Voting Results), but rather the setup/postponement of the AGM.
2020-01-22 English
CURRENT REPORT OF FOREIGN ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a Current Report of Foreign Issuer filed with the SEC. It announces the postponement of the annual shareholders' meeting due to lack of quorum and provides details about the rescheduled meeting date. The document does not contain financial statements or detailed financial analysis, nor does it present the full annual report or interim report. It is a regulatory announcement about a corporate event (postponement of AGM). The document length is 3021 characters, which is relatively short and consistent with a regulatory filing or announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-01-22 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.